13F-HR filed by GREAT POINT PARTNERS LLC
GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2024-09-30, filed 2024-11-13, with 30 holding rows worth $339,761,559.
- Accession
- 0001172661-24-004656
- Filer
- CIK 1281446
- Filed
- 2024-11-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2024
A holdings report, 30 entries on the cover page, a total value of $339,761,559 stated on the cover page (in dollars after the unit check, H1), rows summing to $339,761,559 with VALUE read as dollars as filed, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerJAY JEFFREY R028-12517
- included managerNordahl Lillian
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| NEUROGENE INC | 64135M105 | COMMON STOCK | 1,004,291 | $42,140,050 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 2,128,773 | $24,523,465 | dollars as filed | |
| PLIANT THERAPEUTICS INC | 729139105 | COM | 1,910,121 | $21,412,456 | dollars as filed | |
| EVOLUS INC | 30052C107 | COM | 1,170,000 | $18,954,000 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 750,000 | $17,062,500 | dollars as filed | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 316,000 | $16,684,800 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 1,299,503 | $15,048,245 | dollars as filed | |
| DYNAVAX TECHNOLOGIES CORP | 268158201 | COM NEW | 1,326,234 | $14,774,247 | dollars as filed | |
| CONTEXT THERAPEUTICS INC | 21077P108 | COM | 6,934,982 | $13,592,565 | dollars as filed | |
| ZURA BIO LTD | G9TY5A101 | COMMON STOCK | 3,263,672 | $13,250,508 | dollars as filed | |
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 514,659 | $12,614,292 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 250,000 | $12,490,000 | dollars as filed | |
| OLEMA PHARMACEUTICALS INC | 68062P106 | COM | 1,000,000 | $11,940,000 | dollars as filed | |
| IONIS PHARMACEUTICALS INC COM | 462222100 | Stock | 255,000 | $10,215,300 | dollars as filed | |
| AUTOLUS THERAPEUTICS PLC SPON | 05280R100 | COM | 2,811,955 | $10,207,397 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 758,786 | $9,636,582 | dollars as filed | |
| OPTINOSE INC | 68404V100 | COM | 12,861,136 | $8,616,961 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 100,000 | $8,351,000 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 100,000 | $8,351,000 | dollars as filed | put |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 275,000 | $7,529,500 | dollars as filed | |
| OUTLOOK THERAPEUTICS INC | 69012T305 | COM | 1,293,028 | $6,904,770 | dollars as filed | |
| JASPER THERAPEUTICS INC | 471871202 | COM NEW | 322,380 | $6,063,968 | dollars as filed | |
| VOYAGER THERAPEUTICS INC | 92915B106 | COMMON STOCK | 959,953 | $5,615,725 | dollars as filed | |
| HELIX ACQUISITION CORP II | G4444H101 | CL A ORD SHS | 500,000 | $5,224,950 | dollars as filed | |
| Tscan Therapeutics Inc | 89854M101 | COM | 1,016,375 | $5,061,548 | dollars as filed | |
| UNICYCIVE THERAPEUTICS INC | 90466Y103 | CMN | 8,559,000 | $3,491,216 | dollars as filed | |
| PROMIS NEUROSCIENCES INC | 74346M406 | COM NEW | 2,790,698 | $3,488,373 | dollars as filed | |
| CARTESIAN THERAPEUTICS INC | 816212302 | COMMON STOCK | 200,000 | $3,224,000 | dollars as filed | |
| VISTAGEN THERAPEUTICS INC | 92840H400 | COM | 674,075 | $2,028,966 | dollars as filed | |
| CLIMB BIO INC | 28658R106 | COMMON STOCK | 248,168 | $1,263,175 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001172661-24-004656 | this filing | 2024-11-13 | acceptance time not in the bulk data set |